143 related articles for article (PubMed ID: 1824898)
1. OKT3 resistant rejection in liver transplant patients.
Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
[No Abstract] [Full Text] [Related]
2. Experience with OKT3 after orthotopic liver transplantation.
Stratta R; Shaefer M; Bradshaw K; Wood R; Langnas A; Zetterman R; Donovan J; Sorrell M; Markin R; Shaw BW
Transplant Proc; 1991 Jun; 23(3):1970. PubMed ID: 1829556
[No Abstract] [Full Text] [Related]
3. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.
Renard TH; Andrews WS; Foster ME
Transplant Proc; 1991 Feb; 23(1 Pt 2):1473-6. PubMed ID: 1846468
[No Abstract] [Full Text] [Related]
4. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
5. Prolonged and repeated courses of OKT3 after liver transplantation.
Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
[No Abstract] [Full Text] [Related]
6. Effect of the HLA-DRw6 antigen in liver transplantation.
Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
[No Abstract] [Full Text] [Related]
7. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
8. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
9. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
[No Abstract] [Full Text] [Related]
10. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
11. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
[No Abstract] [Full Text] [Related]
12. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
Sommerauer JF; Atkison P; Howard J; Grant D; Wall W
Transplant Proc; 1994 Feb; 26(1):154-6. PubMed ID: 8108917
[No Abstract] [Full Text] [Related]
13. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
14. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
Burke GW; Vercellotti GM; Simmons RL; Howe RB; Canafax DM; Najarian JS
Transplantation; 1989 Sep; 48(3):403-8. PubMed ID: 2528849
[TBL] [Abstract][Full Text] [Related]
15. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
[No Abstract] [Full Text] [Related]
16. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients.
McDiarmid SV; Millis M; Terashita G; Ament ME; Busuttil R; Terasaki P
Transplant Proc; 1990 Aug; 22(4):1774-6. PubMed ID: 2117806
[No Abstract] [Full Text] [Related]
17. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
18. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
19. Immunohistological analysis of T lymphocyte subpopulations in needle core biopsies from OKT3-treated renal allograft recipients.
Chauhan B; Mohanakumar T; Flye MW
Transplantation; 1990 Dec; 50(6):1058-60. PubMed ID: 2147792
[No Abstract] [Full Text] [Related]
20. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
